Release Summary

Alexion announced that data from an ongoing Phase 1/2 dose-escalation study of ALXN1210 in patients with PNH showed rapid and sustained reductions in LDH in patients treated with once-monthly dosing.

Alexion Pharmaceuticals, Inc.